Updates in Oncology, Palmer/Mt. View
September 12, 2024, from 5:30pm - 7:30pm

1) Bispecific Antibodies and CAR-T cells: Dueling Immunotherapies for Large B cell Lymphomas Bispecific Antibodies for the Treatment of B cell Lymphoma: Promises, Unknowns, and Opportunities

2) CAR-T cells vs. Bispecific Antibody as Third or Later-Line Large B Cell Lymphoma Therapy: A Meta-Analysis

3) Risk of Second Tumors and T cell Lymphoma after CAR-T cell Therapy

Learning Objectives

The learner will be able to:

• Recognize differences in effectiveness between CAR-T and BiTE in relapsed/refractory patients with DLBCL.
• Relate age and disease aggressiveness as markers for treatment selection in relapsed/refractory patients with DLBCL.
• Recall treatment considerations based on toxicity and side effects of CAR-T vs BiTE in relapsed/refractory patients with DLBCL.
• Discuss incidence of emerging data on secondary cancer diagnosis including T-Cell lymphoma after treatment with CAR-T.
• Verbalize monitoring parameters for patient screening to reduce risk of second tumors and T-Cell lymphoma.
• Review the role of TET2 or DNMT3A deficiency in second tumors related to CAR-T treatment.
• Distinguish clinical characteristics, outcomes, and toxicities of CAR-T trials for treatment of large B cell lymphomas
• Examine shortcomings of treatment with CAR-T for lymphoma patients
• Identify ICANS/CRS protocols for CAR-T treatments
• Compare and contrast available Bispecific medications in outcomes and characteristics for treatment of large B cell lymphomas
• Summarize shortcomings for treatment with BiTE for lymphoma patients
• Assess ICANS/CRS protocols for BiTE treatments.
• Develop rationale for choosing treatment (order of administration/sequencing) between CAR-T and BiTE therapies
• Discuss novel combinations treatments emerging for R/R DLBCL
   

Contact Hours

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.  The following information was provided:

Terry Evans and the planning committee for this activity did not have any relevant financial relationships with a commercial interest.